{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:20:26Z","timestamp":1777890026052,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024B1515040027"],"award-info":[{"award-number":["2024B1515040027"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A04J6248"],"award-info":[{"award-number":["2024A04J6248"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020742","name":"State Key Laboratory of Anti-Infective Drug Development","doi-asserted-by":"publisher","award":["2015DQ780357"],"award-info":[{"award-number":["2015DQ780357"]}],"id":[{"id":"10.13039\/100020742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmcl.2026.130629","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:20:31Z","timestamp":1774545631000},"page":"130629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of Pyrazolo[1,5-a]pyridine derivatives as potent RET inhibitors for the treatment of human thyroid and lung Cancer"],"prefix":"10.1016","volume":"137","author":[{"given":"Lin","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangxiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130629_bb0005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2026.130629_bb0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2026.130629_bb0015","first-page":"581","article-title":"Activation of a novel human transforming gene","volume":"42","author":"Takahashi","year":"1985","journal-title":"RET, by DNA rearrangement, Cell"},{"key":"10.1016\/j.bmcl.2026.130629_bb0020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40265-024-02040-5","article-title":"RET inhibitors in RET fusion-positive lung cancers: past, present, and future","volume":"84","author":"Chen","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2026.130629_bb0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0030","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-08-0293","article-title":"RET\/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose","volume":"68","author":"Hamatani","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130629_bb0035","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1200\/JCO.2012.45.8240","article-title":"RET fusion genes in non-small-cell lung cancer","volume":"30","author":"Chao","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.bmcl.2026.130629_bb0040","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.1002\/anie.201302313","article-title":"Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR Threonine790 to Methionine790 (T790M) mutants","volume":"52","author":"Xu","year":"2013","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2026.130629_bb0045","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2026.130629_bb0050","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2165\/11595310-000000000-00000","volume":"71","author":"Commander","year":"2011","journal-title":"Vandetanib Drugs"},{"key":"10.1016\/j.bmcl.2026.130629_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmcl.2026.130629_bb0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"First approval","volume":"80","author":"Selpercatinib","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2026.130629_bb0065","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1200\/JCO.2019.37.15_suppl.6018","article-title":"Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers","volume":"37","author":"Taylor","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0070","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1021\/acs.jmedchem.7b00076","article-title":"Design, synthesis, and pharmacological evaluation of novel multisubstituted pyridin-3-amine derivatives as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer","volume":"60","author":"Zhu","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130629_bb0075","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.jtho.2018.06.021","article-title":"Emergence of a RET V804M gatekeeper mutation during treatment with Vandetanib in RET-rearranged NSCLC","volume":"13","author":"Dagogo-Jack","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0080","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0095","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.012","article-title":"Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma","volume":"158","author":"Shankar","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2026.130629_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2026.130629_bb0110","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0959-8049(16)33028-3","article-title":"The development of LOXO-292, a potent, KDR\/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers","volume":"69","author":"Brandhuber","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2026.130629_bb0115","doi-asserted-by":"crossref","first-page":"73766","DOI":"10.18632\/oncotarget.17900","article-title":"In vitro and in vivo anti-tumor activity of Alectinib in tumor Ccells with NCOA4-RET","volume":"8","author":"Arai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2026.130629_bb0120","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1535-7163.MCT-15-0350","article-title":"Antitumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma","volume":"14","author":"Kang","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2026.130629_bb0125","first-page":"6","article-title":"The L730V\/I RET roof mutations display dfferent activities toward Pralsetinib and Selpercatinib. Npj precision","volume":"5","author":"Shen","year":"2021","journal-title":"Oncology"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:24:50Z","timestamp":1777613090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2600096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"alternative-id":["S0960894X2600096X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130629","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Pyrazolo[1,5-a]pyridine derivatives as potent RET inhibitors for the treatment of human thyroid and lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130629"}}